When immune system T cells find and recognise a target, they release chemicals to attract more T cells which then swarm to help subdue the threat, shows a new study published today in eLife.
The discovery of this swarming behaviour, and the chemical attractants that immune cells use to direct swarms towards tumours, could one day help scientists develop new cancer therapies that boost the immune system.
This is particularly important for solid tumours, which so far have been less responsive to current immunotherapies than cancers affecting blood cells.
“Scientists have previously thought that cancer-killing T cells identified tumours by randomly searching for them or by following the chemical trails laid by other intermediary immune cells,” says lead author Jorge Luis Galeano Niño, a PhD graduate at UNSW Sydney.
“We wanted to investigate this further to see if it’s true, or whether T cells locate tumours via another mechanism.”
Using 3D tumour models grown in the laboratory and in mouse models, the team showed that cancer-killing T cells can home-in on tumour cells independently of intermediary immune cells.
When the T cells find and recognise a tumour, they release chemical signals, which then attract more T cells that sense the signals through a receptor called CCR5, and cause a swarm.
“These cells coordinate their migration in a process reminiscent of the swarming observed in some insects and another type of immune cell called neutrophils, which help the body respond to injury and pathogens,” Galeano Niño says.
After confirming their results using computer modelling, the team genetically engineered human cells called chimeric antigen receptor (CAR)-T cells and showed they also swarm toward a 3D glioblastoma tumour grown in the laboratory.
CAR-T cells are currently being used to treat certain types of blood cancer.
But the new findings suggest that it might also be possible to train these cells to attack solid tumours.
“Although this is fundamental research and at an early stage, the swarming mechanism could be exploited in the future to target CAR-T cells to solid tumours, potentially leading to enhanced immunotherapies that are more effective at infiltrating and destroying these types of tumours,” says senior author Maté Biro, EMBL Australia Group Leader at the Single Molecule Science node, UNSW.
“It will also be important to determine whether silencing the swarming mechanism could be beneficial in dampening overzealous T-cell responses following transplant surgery, in autoimmune conditions, or associated with viral infections,” he adds.